TARRYTOWN, N.Y., Dec. 18, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 37thAnnual J.P. Morgan Healthcare Conference on Monday, January 7, 2019. The presentation is scheduled for 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time) and may
About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuiteŪ technologies, such as VelocImmuneŪ which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:Investor RelationsMark Hudson914firstname.lastname@example.org
Corporate CommunicationsAlexandra Bowie914email@example.com
View original content:http://www.prnewswire.com/news-releases/regeneron-announces-presentation-at-the-37th-annual-jp-morgan-healthcare-conference-300768286.html
SOURCE Regeneron Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!